Market Newsdesk

NEW YORK, Jan. 12, 2026 /PRNewswire/ — 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bitdeer Technologies Group (NASDAQ: BTDR) between June 6, 2024 and November 10, 2025, both dates inclusive (the “Class Period”), of the important February 2, 2026 lead plaintiff deadline.

So what: If you purchased Bitdeer securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Bitdeer class action, go to https://rosenlegal.com/submit-form/?case_id=49102 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants provided investors with material information concerning Bitdeer’s research and technology roadmap for its SEALMINER Bitcoin mining machine. Defendants’ statements included, among other things, confidence in Bitdeer’s mass production of its fourth-generation SEALMINER (A4) rigs using its SEAL04 ASIC (“application-specific integrated circuit”) chip technology expected to have a chip energy efficiency of as low as 5J/TH. Defendants provided these positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concerning material adverse facts concerning the true state of Bitdeer’s SEALMINER A4 project. Specifically, defendants failed to disclose that the SEAL04 chip projected to have a chip-level energy efficiency of 5 J/TH would be ready for use in the A4 rigs with an expected mass production to begin in the second quarter 2025. Such statements absent these material facts caused investors to purchase Bitdeer securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Bitdeer class action, go to https://rosenlegal.com/submit-form/?case_id=49102 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/btdr-investors-have-opportunity-to-leadbitdeer-technologies-group-securities-fraud-lawsuit-302659048.html

SOURCE THE ROSEN LAW FIRM, P. A.

• AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx
• AbbVie will commit $100 billion in U.S. research and development (R&D) and capital investments, including manufacturing, over the next decade
• This three-year agreement provides AbbVie with exemption from tariffs and future pricing mandates

NORTH CHICAGO, Ill., Jan. 12, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans while protecting and investing in U.S. pharmaceutical innovation.

The company will provide low prices in Medicaid while pledging $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade. AbbVie will also expand direct-to-patient offerings through TrumpRx for medicines used by millions of Americans, including ALPHAGAN®, COMBIGAN®, HUMIRA® and SYNTHROID®.

“AbbVie’s mission is to make a remarkable impact for the patients we serve around the world through our innovative medicines,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “With approximately 29,000 U.S.-based employees and products treating 16 million Americans annually, we understand the complexity and access challenges in our healthcare system. AbbVie is following President Trump’s call to action by reaching this agreement, allowing us to collectively move beyond policies that harm American innovation. Thank you to President Trump and his team for their leadership to help deliver cost savings and supporting our efforts to deliver innovative treatments for American patients.”

AbbVie’s agreement, which addresses all four of the President’s drug pricing priorities, was enabled by the Trump administration providing exemption from tariffs and future price mandates, and the government’s continued efforts to ensure global prices reflect the full value of U.S. medical innovation. Further terms of this agreement remain confidential.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter) and YouTube.

Forward-Looking Statements 

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including statements related to the future impact of AbbVie’s voluntary agreement with the U.S. government. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to the ability to realize the anticipated benefits of the voluntary agreement with the U.S. government, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

View original content:https://www.prnewswire.com/news-releases/abbvie-and-trump-administration-reach-agreement-to-improve-access-and-affordability-for-americans-302659062.html

SOURCE AbbVie

FORT WORTH, Texas, Jan. 12, 2026 /PRNewswire/ — Lockheed Martin (NYSE: LMT) welcomed Secretary of War Pete Hegseth to the Fort Worth, Texas, F-35 Lightning II production facility today. The visit was part of the secretary’s Arsenal of Freedom industry tour and underscored Lockheed Martin’s role in accelerating acquisition transformation and delivering critical capabilities to the warfighter.

During the tour, Hegseth toured the F-35 assembly line, met with Lockheed Martin leaders and addressed more than 600 of the 19,000 Fort Worth employees.

“I’m looking out into an incredible audience of Americans here who are committed to an incredible company that’s building incredible platforms,” Hegseth said. “Thank you for accepting and grasping the challenge of President Trump as well as our department. Thank you all so much for what you do, for why you’re doing it. We are shoulder to shoulder with you because we can’t deter the next conflict without the skills and capabilities you have.”

Over 1,900 suppliers across the United States, more than half of which are small businesses, contribute to the F-35 supply chain. Propelled by the strength of American manufacturing, annual F-35 production is running at a pace five times faster than any other allied fighter currently in production, underscoring the program’s scale and maturity.

“The F-35 is the most advanced multi-mission fighter jet in the world as clearly shown in many recent and successful military engagements around the world. Our U.S. Air Force, Navy, and Marine F-35 pilots, along with those of our allies, ensure air superiority when they take to the skies, and are critical contributors to President Trump’s strategy of peace through strength,” said Jim Taiclet, chairman, president and CEO of Lockheed Martin.

“It was an honor to host Secretary of War Hegseth during his visit to our F-35 production operation in Fort Worth, Texas, and introduce him to members of our amazing workforce who in 2025 delivered a record number of 191 fighter jets. Every one of our 19,000 employees at the Fort Worth plant, and many more at our own and our suppliers’ factories around the country, are totally dedicated to building these jets faster and more efficiently. It was great to hear their dedication and excitement in speaking to Secretary Hegseth about their work during our visit.”

Beyond aircraft production, the company announced a landmark framework agreement with the U.S. Department of War last week to rapidly accelerate the production and delivery of PAC-3® Missile Segment Enhancement (MSE) interceptors – the first example of the Acquisition Transformation Strategy being put into action.

About the F-35

More than 1,290 F-35s are currently operational around the globe, and the fleet surpassed 1 million flight hours in 2025. The combat proven F-35 operates from 50 bases worldwide, including 11 nations operating on home soil. As adversaries advance and legacy aircraft age, the F-35 is critical to maintaining air dominance for decades to come.

About Lockheed Martin

Lockheed Martin is a global defense technology company driving innovation and advancing scientific discovery. Our all-domain mission solutions and 21st Century Security® vision accelerate the delivery of transformative technologies to ensure those we serve always stay ahead of ready. More information at Lockheedmartin.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/secretary-of-war-visits-lockheed-martin-f-35-production-facility-302659030.html

SOURCE Lockheed Martin Aeronautics

NEW YORK, Jan. 12, 2026 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DeFi Technologies, Inc. (NASDAQ: DEFT) between May 12, 2025 and November 14, 2025, both dates inclusive (the “Class Period”), of the important January 30, 2026 lead plaintiff deadline.

So What: If you purchased DeFi Technologies securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do Next: To join the DeFi Technologies class action, go to https://rosenlegal.com/submit-form/?case_id=48771 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 30, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the Case: According to the lawsuit,  defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) DeFi Technologies was facing delays in executing its DeFi arbitrage strategy, which at all relevant times was a key revenue driver for DeFi Technologies; (2) DeFi Technologies had understated the extent of competition it faced from other digital asset treasury (“DAT”) companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (3) as a result of the foregoing issues, DeFi Technologies was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (4) accordingly, defendants had downplayed the true scope and severity of the negative impact that the foregoing issues were having on DeFi Technologies’ business and financial results; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DeFi Technologies class action, go to https://rosenlegal.com/submit-form/?case_id=48771 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/deft-investors-have-opportunity-to-lead-defi-technologies-inc-securities-fraud-lawsuit-302658790.html

SOURCE THE ROSEN LAW FIRM, P. A.